222 related articles for article (PubMed ID: 23233725)
41. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
42. Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection.
LaRocque-de-Freitas IF; Rocha JDB; Nunes MP; Oliveira PAV; Nascimento DO; Freire-de-Lima L; Takiya CM; Morrot A; Decote-Ricardo D; Previato JO; DosReis GA; Mendonça-Previato L; Freire-de-Lima CG
Sci Rep; 2018 Nov; 8(1):16378. PubMed ID: 30401972
[TBL] [Abstract][Full Text] [Related]
43. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
44. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
45. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.
McClelland EE; Nicola AM; Prados-Rosales R; Casadevall A
J Clin Invest; 2010 Apr; 120(4):1355-61. PubMed ID: 20335660
[TBL] [Abstract][Full Text] [Related]
46. Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.
Lee HH; Del Pozzo J; Salamanca SA; Hernandez H; Martinez LR
Fungal Genet Biol; 2019 Nov; 132():103258. PubMed ID: 31356873
[TBL] [Abstract][Full Text] [Related]
47. Polysaccharide antigens of the capsule of Cryptococcus neoformans.
Cherniak R; Sundstrom JB
Infect Immun; 1994 May; 62(5):1507-12. PubMed ID: 8168912
[TBL] [Abstract][Full Text] [Related]
48. Immunity in cryptococcosis: an overview.
Fromtling RA; Shadomy HJ
Mycopathologia; 1982 Mar; 77(3):183-90. PubMed ID: 7040977
[TBL] [Abstract][Full Text] [Related]
49. Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells.
Araujo Gde S; Fonseca FL; Pontes B; Torres A; Cordero RJ; Zancopé-Oliveira RM; Casadevall A; Viana NB; Nimrichter L; Rodrigues ML; Garcia ES; Souza Wd; Frases S
PLoS One; 2012; 7(1):e29561. PubMed ID: 22253734
[TBL] [Abstract][Full Text] [Related]
50. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
[TBL] [Abstract][Full Text] [Related]
51. [The evaluation of the specific type of capsular polysaccharide of Cryptococcus neoformans as an immunogen and positive-control antigen].
Toraño Peraza GT; Rodríguez Acebo W; Martínez Machín G
Rev Cubana Med Trop; 1998; 50(3):207-8. PubMed ID: 10349445
[TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
53. Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules.
Frases S; Pontes B; Nimrichter L; Viana NB; Rodrigues ML; Casadevall A
Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1228-33. PubMed ID: 19164571
[TBL] [Abstract][Full Text] [Related]
54. Cryptococcus neoformans capsule regrowth experiments reveal dynamics of enlargement and architecture.
Wear MP; Jacobs E; Wang S; McConnell SA; Bowen A; Strother C; Cordero RJB; Crawford CJ; Casadevall A
J Biol Chem; 2022 Apr; 298(4):101769. PubMed ID: 35218774
[TBL] [Abstract][Full Text] [Related]
55. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
56. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
57. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
[TBL] [Abstract][Full Text] [Related]
58. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
[TBL] [Abstract][Full Text] [Related]
59. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
60. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y
Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
